Amoy Diagnostics Co. Ltd. (ADx) and Illumina, Inc. (ILMN) today announced a strategic collaboration to accelerate the adoption of precision medicine and targeted therapies in China.
Under the collaboration, Amoy will develop and commercialize a series of oncology-related tests based on Illumina’s next-generation sequencing (NGS) platforms, including the recently released research use only TruSight Tumor 15 as transferred from Illumina to Amoy.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”